Pharmacological evaluation of novel 5-HT 3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery | Zendy

Deepali Gupta | Zendy; Mahesh Radhakrishnan | Zendy; Thangaraj Devadoss | Zendy; Yeshwant Kurhe | Zendy

Open Access

Pharmacological evaluation of novel 5-HT ₃ receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery

Author(s) -

Deepali Gupta,

Mahesh Radhakrishnan,

Thangaraj Devadoss,

Yeshwant Kurhe

Publication year - 2015

Publication title -

journal of pharmacy and bioallied sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.268

H-Index - 36

eISSN - 0976-4879

pISSN - 0975-7406

DOI - 10.4103/0975-7406.154429

Subject(s) - antagonist , anxiety , pharmacology , battery (electricity) , carboxamide , medicine , neuroscience , psychology , psychiatry , chemistry , receptor , stereochemistry , physics , power (physics) , quantum mechanics

In the last few decades, serotonin type-3 (5-HT3) receptor antagonists have been identified as potential targets for anxiety disorders. In preclinical studies, 5-HT3 antagonists have shown promising antianxiety effects. In this study, a novel 5-HT3 receptor antagonist, QCM-13(N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) was evaluated for anxiolytic-like activity in rodent behavioral test battery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research